Alnylam Pharmaceuticals I... (ALNY)

AI Score

Unlock

241.97

5.22 (2.20%)

At close: Apr 23, 2025, 3:59 PM

241.89

-0.03%

Pre-market: Apr 24, 2025, 04:23 AM EDT

Dividends

No dividend history available for Alnylam Pharmaceuticals Inc..

Pro Subscription

Upgrade now for unlimited access to all data and tools.

Dividend Definition

Dividends are payments made by a company to its shareholders, typically derived from its profits. They represent a portion of earnings distributed to investors as a reward for holding shares. Dividends do not account for retained earnings or reinvestments and are therefore different from a company's total profits.

Full Definition

Related Stocks

Company	Dividend Yield

Dividend Rankings

ALNY News

1 week ago · Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results - businesswire.com
1 week ago · Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? - zacks.com
3 weeks ago · Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference - businesswire.com
3 weeks ago · Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 - businesswire.com
3 weeks ago · FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B - businesswire.com
1 month ago · Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - benzinga.com
1 month ago · Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? - zacks.com
1 month ago · Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster - seekingalpha.com
1 month ago · Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy - zacks.com
1 month ago · Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps - benzinga.com